Coloplast A/s Class B · OMXCOP:COLO_B
Coloplast A/s Class B — H1 2016/17 Earnings Presentation
8 slides from Coloplast A/s Class B's earnings presentation, May 3, 2017
Slide 1: Coloplast Earnings Conference Call H1 2016/17
Coloplast Earnings Conference Call H1 2016/17 3 May 2017
Slide 2: Forward-looking statements
Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements
Slide 3: Coloplast delivered Q2 organic growth of 7% and 32% EBIT margin in constant currencies
Coloplast delivered Q2 organic growth of 7% and 32% EBIT margin in constant currencies Q2 Highlights Revenue growth +6% • Q2 organic growth of 7% (8% in DKK) Reported revenue (DKKm) +5% • The acquisition of Comfort Medical Organic growth +8% 7,636 7,256 contributed ~2% growth to revenue Reported gro
Slide 4: LEAD20 – an update on our direction towards 2020
LEAD20 – an update on our direction towards 2020 Superior products and innovation Unique user-focused market Unparalleled efficiency approach SenSura® Mio Innovation Excellence Hospital Assortment Production ramp-up directly from Launched in 2017 Hungary/China: SenSura® Mio Convex + 500,000 enrolmen
Slide 5: H1 organic growth of 6% heavily impacted by inventory reductions at large distributors in the US in Q1
H1 organic growth of 6% heavily impacted by inventory reductions at large distributors in the US in Q1 H1 16/17 revenue by business area H1 16/17 revenue by geography Business Reported revenue Organic growth Share of organic Geographic Reported revenue Organic growth Share of organic area DKKm growt
Slide 6: H1 operating margin of 33% in constant currencies and 32% in DKK
H1 operating margin of 33% in constant currencies and 32% in DKK Comments Performance • EBIT before special items grew 5% in DKK (8% in constant currencies) to DKK 2,472m with a reported margin of 32% (33% in constant currencies) 0.5 compared to 33% last year 32.7 32.5 -0.2 • Gross margin of 68% in
Slide 7: Unchanged financial guidance for 2016/17
Unchanged financial guidance for 2016/17 Guidance 16/17 Guidance 16/17 (DKK) Long term ambition Sales growth 7-8% (organic) 7-8% 7-9% p.a. 33-34% (constant EBIT margin ~33 +50-100 bps p.a. exchange rates) CAPEX (DKKm) ~700 4-5% of sales Tax rate ~23 Page 7
Slide 8: Our mission, values and vision
Our mission Making life easier for peoplé with intimate healthcare needs Our values Closeness... to better understand. - Passion... to make a difference Respect and responsibility... to 0 guide | US: Our vision Setting the global standard for listening and responding: Coloplast A/S - Ostomy Care / C